REGN
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc historical holders
total: 8
Oakmark Select Fund Regeneron Pharmaceuticals Inc transactions over time
- Total transactions:
- 9
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 6
- Held since:
- 2019 Q3
- Held for:
- 11 quarters
- Latest activity:
- 2022 Q2
Bill Nygren has been an institutional investor in Regeneron Pharmaceuticals Inc (REGN) since 2019 Q3. According to 2026 Q1 report, Bill Nygren doesn't hold any shares. The fund/company first acquired REGN in 2019 Q3, initially purchasing 620,000 shares. Since the initial investment, Oakmark Select Fund has made 8 more transactions in this position.
When did Bill Nygren exit their REGN position?
Bill Nygren no longer holds Regeneron Pharmaceuticals Inc (REGN). They sold off their entire position in 2022 Q2, closing out an investment that began in 2019 Q3.
When did Bill Nygren first invest in REGN?
Bill Nygren first invested in Regeneron Pharmaceuticals Inc (REGN) in 2019 Q3 at the reported quarter-end price of $277.40 per share, acquiring 620,000 shares in their initial purchase.
What is Bill Nygren's average cost basis for REGN?
Based on historical transaction data, Bill Nygren's estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) is approximately $366.99 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $366.99
- Weighted AVG sell price:
- $583.19
REGN transactions history by Oakmark Select Fund
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q2
|
0.00%
|
0
|
$698.42
|
|
-100% (-224,000)
|
-2.93%
|
|
2022 Q1
|
2.93%
|
224,000
|
$698.42
|
$156,446,080
|
-22.76% (-66,000)
|
-0.82%
|
|
2021 Q3
|
3.23%
|
290,000
|
$605.18
|
$175,502,200
|
-6.45% (-20,000)
|
-0.23%
|
|
2021 Q2
|
3.34%
|
310,000
|
$558.54
|
$173,147,400
|
+1,450.00% (+290,000)
|
+3.12%
|
|
2020 Q4
|
0.23%
|
$483.11
|
-83.92% (-104,400)
|
|||
|
2020 Q3
|
2.05%
|
$559.78
|
-59.13% (-180,000)
|
|||
|
2020 Q2
|
5.31%
|
$623.65
|
-20.71% (-79,491)
|
|||
|
2020 Q1
|
5.80%
|
$488.29
|
-38.08% (-236,109)
|
|||
|
2019 Q3
|
3.86%
|
$277.40
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.